Vaniqa (eflornithine HCl) Cream 13.9%

Manufacturer: Bristol-Myers Squibb & Gillette Co.  

Indication(s):  Reduction of unwanted facial hair growth in women

Dosage & Administration:  Application of a thin layer should be twice daily at least 8 hours apart and rubbed in well.

Pharmacology:  Inhibition of ornithine decarboxylase (ODC) which is necessary for synthetic functions and cell division.

WebRx Editorial Notes:  Effective in slowing the growth of facial hair in 60% of women.  The product takes up to two months to work and women will need to continue to use previous methods of hair removal as well indefinitely.  Though Vaniqa's purpose is only cosmetic, proper evaluation should be performed by a health professional to rule out potential underlying diseases such as androgen excess disorder or polycystic ovarian syndrome.

2001, 2002 WebRx Pharmacy Palace